Hematologic Malignancy
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00005967PTCLExplore in graph →
Hematologic172 active trials13 approved drugs9 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005967PTCLExplore in graph →
Clinical trials
786 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (129)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05949944 | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03922724 | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | active not recruiting | Phase 2 | 91 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04960618 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | active not recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04984837 | Study of Lacutamab in Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 4 | Jun 4, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT04417166 | Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | active not recruiting | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | active not recruiting | Phase 2 | 50 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03385226 | A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)(PORT) | active not recruiting | Phase 2 | 46 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06550336 | A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). | active not recruiting | Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials